Celebrity Inventors
Glam girl Heddy Lamar may have used her good looks to good effect on the silver screen, but she put her smarts to better use as an inventor. During World War II, she co-patented a frequency-switching system for torpedo guidance that was considered years ahead of its time.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| RE40811 | Peripheralization of hematopoietic stem cells The invention relates to in vivo peripheralization of CD34+ cells by administering anti-VLA-4 antibodies or anti-VCAM-1 antibodies. ... | 06/30/2009 |
| 7541437 | Breast cancer resistance protein (BCRP) and the DNA which encode it The Breast Cancer Resistance Protein is described, as well as the cDNA encoding said protein. This protein has been found to confer resistance to cancer chemotherapeutic drugs. ... | 06/02/2009 |
| 7449181 | Remedies for cancer A medicament for treating cancer for use in combination therapy with an anti-HER2 antibody, which comprises amrubicin or a pharmaceutically acceptable salt thereof as an active ingredient. ... | 11/11/2008 |
| 7429452 | Methods for diagnosis and therapy of pancreatic cancer and composition useful therein Polynucleotide and polypeptide UKW are specific for pancreatic tumors. Diagnosis of UKW is therefore valuable for diagnosis of pancreatic tumors. Antibodies against UKW are, besides their value in diagnosis, useful as therapeutic agents for the treatment of pancreat... | 09/30/2008 |
| 7427399 | Antibodies and related molecules that bind to 161P2F10B proteins Antibodies and molecules derived therefrom that bind to 161P2F10B protein and variants thereof, are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 16... | 09/23/2008 |
| 7419807 | protein, gene sequence and uses thereof A high molecular weight (“HMW”) protein of Chlamydia, the amino acid sequence thereof, and antibodies that specifically bind the HMW protein are disclosed as well as the nucleic acid sequence encoding the same. Also disclosed are prophylactic and therapeu... | 09/02/2008 |
| 7416862 | Nucleic acid and amino acid sequences relating to for diagnostics and therapeutics The invention provides isolated polypeptide and nucleic acid sequences derived from Staphylococcus epidermidis that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the poly... | 08/26/2008 |
| 7407656 | PSCA: prostate stem cell antigen and uses thereof The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and an... | 08/05/2008 |
| 7405077 | Sperm protein 17 for the diagnosis and treatment of cancer The results herein identify Sp17 as a novel cancer-testis antigen in multiple myeloma. Sp17 recombinant protein was generated from E. coli. A CD8 predominant CTL line was generated that was able to lyse autologous targets in a Sp17-dependent HLA class I-restr... | 07/29/2008 |
| 7393531 | Cytotoxicity mediation of cells evidencing surface expression of MCSP This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more ... | 07/01/2008 |
| 7388071 | Composition and method for inducing and enhancing a telomerase reverse transcriptase-reactive cytotoxic T lymphocyte response Telomerase peptides that bind MHC are disclosed. The instant application also discloses vaccines containing said peptides and methods of using said peptides to enhance a CTL response against mammalian cancer cells. ... | 06/17/2008 |
| 7381407 | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen The present invention relates to monoclonal antibodies that bind to the extracellular domain of prostate-specific membrane antigen (PSMA), hybridoma cell lines producing the antibodies, and methods of using such antibodies for diagnosis and treatment of cancer. In p... | 06/03/2008 |
| 7381701 | Compositions and methods for treating conditions related to ephrin signaling with cupredoxins The present invention relates to compositions and methods of use of cupredoxins, and variants, derivatives and structural equivalents of cupredoxins that interfere with the ephrin signaling system in mammalian cells. Specifically, the invention relates to compositio... | 06/03/2008 |
| 7375183 | Mesothelin, immunogenic peptides derived therefrom, and compositions comprising mesothelin, or immunogenic peptides thereof This invention relates to the discovery of a differentiation antigen termed mesothelin which is associated with mesotheliomas and ovarian cancers. Mesothelin is about 69 kD in its full-length form. The invention includes uses for the amino acid and nucleic acid sequ... | 05/20/2008 |
| 7368261 | Conserved antigens To ensure maximum cross-strain recognition and reactivity, regions of proteins that are conserved between different Neisserial species, serogroups and strains can be used. The invention provides proteins which comprise stretches of amino acid sequence that are share... | 05/06/2008 |
| 7364743 | Nucleotide sequence encoding PTD and CEA fusion protein, TAT-CEA fusion protein, anti-tumor vaccine and pharmaceutical composition for treating tumor comprising the fusion protein A nucleotide sequence encoding a fusion protein of PTD and CEA. The nucleotide sequence includes a CEA-encoding nucleotide sequence into which a PTD-encoding nucleotide sequence is inserted. ... | 04/29/2008 |
| 7361343 | Cytotoxicity mediation of cells evidencing surface expression of CD63 This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more ... | 04/22/2008 |
| 7361354 | Methods for treating malignancies expressing ICAM-1 using coxsackie a group viruses There is disclosed a method of killing abnormal cells such as malignant cells including melanoma cells, using a virus recognizing at least one of a cell adhesion molecule and a complement regulatory protein. The virus may be a member of the Picornaviridae family. Co... | 04/22/2008 |
| 7361342 | Cancerous disease modifying antibodies The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the produ... | 04/22/2008 |
| 7358347 | , the gene associated with multiple endocrine neoplasia type 1, menin polypeptides and uses thereof The invention relates to the discovery of a novel tumor suppressor gene which is associated with multiple endocrine neoplasia type 1. The gene has been designated MEN1 and the gene product is menin. The absence of this protein and associated mutations in the corresp... | 04/15/2008 |
| 7354583 | Antibody-induced apoptosis Anti-Her2 antibodies which induce apoptosis in Her2 expressing cells are disclosed. The antibodies are used to “tag” Her2 overexpressing tumors for elimination by the host immune system. Also disclosed are hybridoma cell lines producing the antibodies, methods f... | 04/08/2008 |
| 7348412 | Ouabain-specific monoclonal antibodies The invention relates to a monoclonal antibody or antigen binding fragment thereof having binding specificity for ouabain, wherein the antibody or antigen binding fragment does not crossreact with digoxin. Preferably the anti-ouabain monoclonal antibody can bind oua... | 03/25/2008 |
| 7344829 | Methods for detecting the efficacy of anticancer treatments Methods for determining the effectiveness of anticancer agents by determining and comparing growth factor receptor phosphorylation levels in samples obtained by non-invasive procedures before and after anticancer treatments are provided. The invention also provides ... | 03/18/2008 |
| 7344713 | Decreased fat absorption with an anti-lipase antibody A method for the decrease of fat absorption in a mammal, wherein the animal is orally fed an antibody produced against lipase, an enzyme which is required for fat absorption. ... | 03/18/2008 |
| 7341869 | Compositions and methods for treating diabetes The present invention provides an isolated population of cells containing an expressible nucleic acid encoding proinsulin containing a proinsulin cleavage site and a glucose-regulated expressible nucleic acid encoding a protease capable of cleaving the proinsulin cl... | 03/11/2008 |
| 7342100 | Hpr6 mutants and uses thereof Methods and agents that interfere with Hpr6 function in non-sarcoma tumor cells are disclosed. Anti-Hpr6 agents are used to enhance the killing effect of anti-cancer agents in non-sarcoma tumor cells and to teat non-sarcoma tumors. ... | 03/11/2008 |
| 7338767 | Use of microphthalmia for diagnosis, prognosis and/or treatment of melanoma Microphthalmia (Mi) while present in melanocytes, a cells and osteoclast, is not normally present in other cells. We have found that Mi is present in the nucleus of melanoma cells. Melanoma can be diagnosed by contacting a malignant cell with a probe for Mi. If the ... | 03/04/2008 |
| 7338766 | Compositions and methods for treating malaria with cupredoxin and cytochrome The present invention relates to cupredoxin and cytochrome and their use, separately or together, to inhibit the spread of parasitemia in mammalian red blood cells and other tissues infected by the malaria parasite, and in particular the parasitemia of human red blo... | 03/04/2008 |
| 7335749 | Tumor suppressor gene, p47Ing3 The invention provides isolated nucleic acid and amino acid sequences of novel human tumor suppressors, antibodies to such tumor suppressors, methods of detecting such nucleic acids and proteins, methods of screening for modulators of tumor suppressors, and methods ... | 02/26/2008 |
| 7329738 | Assays for detection of This invention provides novel methods, reagents, and kits that are useful for detecting B. anthracis. The methods are based on the discovery of binding agents, including recombinant polyclonal antibodies, which bind to the surface array protein of B. anthr... | 02/12/2008 |
| 7323173 | Methods for treating breast cancer using a mammary cell growth inhibitor Mammastatin has an approximate molecular weight of 44 kDa in its inactive, non-phosphorylated form. Normal mammary cells express functional phosphorylated forms having approximate molecular weights of 53 kDa and 49 kDa. Metastatic mammary cells either do not express... | 01/29/2008 |
| 7319010 | Detection and treatment of cancers of the colon The present invention relates to compositions and methods for cancer therapies and diagnostics, including but not limited to, cancer markers. In particular, the present invention provides tumor antigens associated with specific cancers and diagnostic assays for the ... | 01/15/2008 |
| 7319011 | Method for distinguishing follicular thyroid adenoma (FTA) from follicular thyroid carcinoma (FTC) Follicular thyroid adenoma (FTA) is distinguished from follicular thyroid carcinoma (FTC) by comparing amount of an expression product of at least one gene selected from the group consisting of DDIT3, ARG2, ITM1, C1orf24, TARSH, and ACO1 in a test follicular thyroid... | 01/15/2008 |
| 7316906 | CD38 as a prognostic indicator in B cell chronic lymphocytic leukemia The subject invention discloses a method for determining the prognosis and probable clinical course of a subject diagnosed with B-CLL. Specifically, the invention involves comparing CD38 expression in a biological sample from the subject containing B-CLL cells to a ... | 01/08/2008 |
| 7314709 | Compositions and methods for detecting and quantifying COX-2 activity by lipoamino acid metabolism A method of detecting an activity of a COX-2 enzyme in a subject that includes obtaining a sample of the subject; detecting an amino acid eicosanoid metabolite in the sample, wherein the presence of the amino acid eicosanoid metabolite indicates the activity of the ... | 01/01/2008 |
| 7314721 | Small cell lung cancer associated antigens and uses therefor Cancer associated antigens have been identified by autologous antibody screening of libraries of nucleic acids expressed in small cell lung cancer cells using antisera from cancer patients. The invention relates to nucleic acids and encoded polypeptides which are ca... | 01/01/2008 |
| 7311911 | Methods for inhibiting angiogenesis The present invention provides methods for reducing or inhibiting angiogenesis in a tissue, by contacting α5β1 integrin in the tissue with an agent that interferes with the specific binding of α5β1 integrin to a ligand expressed in the tissue; and methods of ide... | 12/25/2007 |
| 7306806 | Recombinant merozoite protein-142 vaccine In this application is the expression and purification of a recombinant Plasmodium falciparum (3D7) MSP-142. The method of the present invention produces a highly purified protein which retains folding and disulfide bridging of the native molecule.... | 12/11/2007 |
| 7297341 | Chlamydia antigens and corresponding DNA fragments and uses thereof The present invention provides purified and isolated polynucleotide molecules that encode Chlamydia polypeptides which can be used in methods to prevent, treat, and diagnose Chlamydia infection. In one form of the invention, the polynucleotide molecule... | 11/20/2007 |
| 7294468 | Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments The present invention is directed to a method for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) treatment. In a preferred embodiment, the presence of at least one variance in the kinase domain of the erbB1 gene confers sensit... | 11/13/2007 |
